A comparison between different postoperative treatment modalities of uterine carcinosarcoma

Gynecologic Oncology

Volumn 97, Issue 1, 2005, Pages 166-170

  Menczer, Joseph ^a,b   Levy, Tally ^a,b   Piura, Benjamin ^c   Chetrit, Angela ^d   Altaras, Marco ^b,e   Meirovitz, Mihai ^c   Glezerman, Marek ^a,b   Fishman, Ami ^b,e  

^a WOLFSON MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^d GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

^e MEIR MEDICAL CENTER   (Israel)

Author keywords

Carcinosarcoma; Chemotherapy; Radiotherapy; Sequential therapy

Indexed keywords

CISPLATIN; IFOSFAMIDE; MESNA;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BONE MARROW DEPRESSION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; IRRADIATION; KAPLAN MEIER METHOD; MEDICAL RECORD; NEUROTOXICITY; PELVIS; POSTOPERATIVE CARE; PRIORITY JOURNAL; REGRESSION ANALYSIS; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; UTERUS CARCINOMA; UTERUS SARCOMA;

EID: 15544374557     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.12.006     Document Type: Article

References (42)

1. A. Gadducci, E. Sartori, F. Landoni, P. Zola, T. Maggino, and S. Cosio The prognostic relevance of histological type in uterine sarcomas: a cooperation task force (CTF) multivariate analysis of 249 cases Eur. J. Gynecol. Oncol. 23 2002 295 299
2. S.G. Silverberg, F.J. Major, J.A. Blessing, B. Fetter, F.B. Askin, and S.Y. Liao Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A gynecologic oncology group pathologic study of 203 cases Int. J. Gynecol. Pathol. 9 1990 1 19
3. M. Guarino, F. Giordano, F. Pallotti, G. Polizzoti, P. Tricomi, and E. Cristofori Malignant mixed Mullerian tumor of the uterus. Feature favoring its origin from a common cell clone and an epithelial to mesenchimal transformation of histogenesis Tumori 84 1998 391 397
4. W.G. McCluggage Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas Int. J. Gynecol. Cancer 12 2002 687 690
5. A. Abargel, I. Avinoach, V. Kravtsov, M. Boaz, M. Glezerman, and J. Menczer Expression of p27 and p53: comparative analysis of uterine carcinosarcoma and endometrial carcinoma Int. J. Gynecol. Cancer 14 2004 354 359
6. F. Amant, L. Dreyer, J. Makin, I. Vergote, and B.G. Lindeque Uterine sarcomas in South African black women: a clinicopathologic study with ethnic considerations Eur. J. Gynaecol. Oncol. 22 2001 194 200
7. S.E. Brooks, M. Zhan, T. Cote, and C.R. Baquet Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999 Gynecol. Oncol. 93 2004 204 208
8. I. Kloos, S. Delaloge, P. Pautier, M. Di Palma, A. Goupil, and P. Duvillard Tamoxifen-related uterine carcinosarcomas occur under/after prolonged treatment: report of five cases and review of the literature Int. J. Gynecol. Cancer 12 2002 496 500
9. F.J. Major, J.A. Blessing, S.G. Silverberg, C.P. Morrow, W.T. Creasman, and J.L. Currie Prognostic factors in early-stage uterine sarcoma. A gynecologic oncology group study Cancer 15 71 1993 1702 1709
10. E. Sartori, L. Bazzurini, A. Gadducci, F. Landoni, A. Lissoni, and T. Maggino Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study Gynecol. Oncol. 67 1997 70 75
11. P.G. Rose, J.G. Boutselis, and L. Sachs Adjuvant therapy for stage I sarcoma Am. J. Obstet. Gynecol. 156 1987 660 662
12. T. Le Adjuvant pelvic radiotherapy for uterine carcinosarcoma in a high risk population Eur. J. Surg. Oncol. 27 2001 282 285
13. B. Larson, C. Silfversward, B. Nilsson, and F. Pettersson Mixed mullerian tumours of the uterus-prognostic factors: a clinical and histopathologic study of 147 cases Radiother. Oncol. 17 1990 123 132
14. W. Hoffmann, S. Schmandt, R.D. Kortmann, M. Schiebe, J. Dietl, and M Bamberg Radiotherapy in the treatment of uterine sarcomas. A retrospective analysis of 54 cases Gynecol. Obstet. Invest. 42 1996 49 57
15. T.H. Knocke, H. Kucera, D. Dorfler, B. Pokrajac, and R. Potter Results of postoperative radiotherapy in the treatment of sarcoma of the corpus uteri Cancer 83 1998 1972 1979
16. K. Gerszten, C. Faul, S. Kounelis, Q. Huang, J. Kelley, and M.W. Jones The impact of adjuvant radiotherapy on carcinosarcoma of the uterus Gynecol. Oncol. 68 1998 8 13
17. F. Ferrer, S. Sabater, B. Farrus, F. Guedea, A. Rovirosa, and L. Anglada Impact of radiotherapy on local control and survival in uterine sarcomas: a retrospective study from the grup oncologic catala-occita Int. J. Radiat. Oncol. Biol. Phys. 44 1999 47 52
18. B. Sorbe Radiotherapy and/or chemotherapy as adjuvant treatment of uterine sarcomas Gynecol. Oncol. 20 1985 281 289
19. E.I. Kohorn, P.E. Schwartz, J.T. Chambers, R.E. Peschel, D.S. Kapp, and M. Merino Adjuvant therapy in mixed mullerian tumors of the uterus Gynecol. Oncol. 23 1986 212 221
20. S.D. Tinkler, and V.J. Cowie Uterine sarcomas: a review of the Edinburgh experience from 1974 to 1992 Br. J. Radiol. 66 1993 998 1001
21. D.S. Chi, B. Mychalczak, P.E. Saigo, J. Rescigno, and C.L. Brown The role of whole pelvic irradiation in the treatment of early-stage uterine carcinosarcoma Gynecol. Oncol. 65 1997 493 498
22. S.D. Yamada, R.A. Burger, W.R. Brewster, D. Anton, M.F. Kohler, and B.J. Monk Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus Cancer 88 2000 2782 2786
23. N.B. Hornback, G. Omura, and F.J. Major Observations on the use of adjuvant radiation therapy in patients with stage I and II uterine sarcoma Int. J. Radiat. Oncol. Biol. Phys. 12 1986 2127 2130
24. A. Gadducci, M.G. Fabrini, V. Facchini, F. Ducci, S. Colosimo, and T. Dell'Arciprete Surgery and radiotherapy in the treatment of early stage uterine sarcomas Eur. J. Gynaecol. Oncol. 10 1989 276 280
25. G. Echt, J. Jepson, J. Steel, B. Langholz, G. Luxton, and W. Hernandez Treatment of uterine sarcomas Cancer 66 1990 35 39
26. L. Chauveinc, E. Deniaud, C. Plancher, X. Sastre, F. Amsani, and A. de la Rochefordiere Uterine sarcomas: the Curie Institute experience. Prognosis factors and adjuvant treatments Gynecol. Oncol. 72 1999 232 237
27. A. Gadducci, and A. Romanini Adjuvant chemotherapy in early stage uterine sarcomas: an open question Eur. J. Gynaecol. Oncol. 22 2001 352 357
28. R. Asbury, J.A. Blessing, E. Podczaski, and H. Ball A phase II trial of amonafide in patients with mixed mesodermal tumors of the uterus: a gynecologic oncology group study Am. J. Clin. Oncol. 21 1998 306 307
29. M.L. Pearl, M. Inagami, D.L. McCauley, F.A. Valea, E. Chalas, and M. Fischer Mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) chemotherapy for gynecological sarcomas Int. J. Gynecol. Cancer 12 2002 745 748
30. J.M. Fowler, J.A. Blessing, R.A. Burger, and J.H. Malfetano Phase II evaluation of oral trimetrexate in mixed mesodermal tumors of the uterus: a gynecologic oncology group study Gynecol. Oncol. 85 2002 311 314
31. A. Szantho, J. Balega, I. Szabo, A. Demeter, N. Sipos, and Z. Csapo Adjuvant chemotherapy following surgery in the management of uterine sarcomas Eur. J. Gynaecol. Oncol. 24 2003 421 424
32. J.L. Currie, J.A. Blessing, R. McGehee, J.T. Soper, and M. Berman Phase II trial of hydroxyurea, dacarbazine (DTIC), and etoposide (VP-16) in mixed mesodermal tumors of the uterus: a gynecologic oncology group study Gynecol. Oncol. 61 1996 94 96
33. R.E. Hempling, M.S. Piver, and T.R. Baker Impact on progression-free survival of adjuvant cyclophosphamide, vincristine, doxorubicin (adriamycin), and dacarbazine (CYVADIC) chemotherapy for stage I uterine sarcoma. A prospective trial Am. J. Clin. Oncol. 18 1995 282 286
34. K. Odunsi, V. Moneke, J. Tammela, S. Ghamande, P. Seago, and D. Driscoll Efficacy of adjuvant CYVADIC chemotherapy in early-stage uterine sarcomas: results of long-term follow-up Int. J. Gynecol. Cancer 14 2004 659 664
35. E. Resnik, S.K. Chambers, M.L. Carcangiu, E.I. Kohorn, P.E. Schwartz, and J.T. Chambers A phase II study of etoposide, cisplatin, and doxorubicin chemotherapy in mixed mullerian tumors (MMT) of the uterus Gynecol. Oncol. 56 1995 370 375
36. W.A. Peters III, S.E. Rivkin, and M.R. Smith Cisplatin and adriamycin combination chemotherapy for uterine stromal sarcomas and mixed mesodermal tumors Gynecol. Oncol. 34 1989 323 327
37. J.P. Curtin, J.A. Blessing, J.T. Soper, and K. DeGeest Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study Gynecol. Oncol. 83 2001 268 270
38. G.P. Sutton, J.A. Blessing, N. Rosenshein, G. Photopulos, and P.J. DiSaia Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study) Am. J. Obstet. Gynecol. 161 1989 309 312
39. T. Thigpen, B.W. Lambuth, and R.B. Vance The role of ifosfamide in gynecologic cancer Semin. Oncol. 19 1992 30 34
40. D.M. Kushner, K.D. Webster, J.L. Belinson, L.A. Rybicki, A.W. Kennedy, and M. Markman Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma Gynecol. Oncol. 78 2000 221 227
41. J.T. Thigpen, J.A. Blessing, J. Beecham, H. Homesley, and E. Yordan Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a gynecologic oncology group study J. Clin. Oncol. 9 1991 1962 1966
42. G. Sutton, V.L. Brunetto, L. Kilgore, J.T. Soper, R. McGehee, and G. Olt A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a gynecologic oncology group study Gynecol. Oncol. 79 2000 147 153